Vera Therapeutics Announces Board and Officer Changes
Ticker: VERA · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1831828
| Field | Detail |
|---|---|
| Company | Vera Therapeutics, INC. (VERA) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, management-change, filing
TL;DR
Vera Therapeutics shuffled its board and execs, filing changes on 12/18.
AI Summary
Vera Therapeutics, Inc. announced on December 16, 2025, changes in its board and officer appointments. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for its key executives. These changes were officially filed with the SEC on December 18, 2025.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure regarding board and officer changes, with no immediate financial or operational impact indicated.
Key Players & Entities
- Vera Therapeutics, Inc. (company) — Registrant
- December 16, 2025 (date) — Earliest event reported
- December 18, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- 2000 Sierra Point Parkway, Suite 1200, Brisbane, California 94005 (address) — Principal Executive Offices
- (650) 770-0077 (phone_number) — Registrant's Telephone Number
FAQ
What specific roles were affected by the departure of officers or directors?
The filing indicates the departure of 'Directors or Certain Officers' and 'Appointment of Certain Officers' but does not specify the exact roles in this excerpt.
Were there any new directors elected to the board?
Yes, the filing explicitly mentions the 'Election of Directors' as an item reported.
What is the nature of the changes in compensatory arrangements?
The filing notes 'Compensatory Arrangements of Certain Officers' were part of the reported items, suggesting adjustments or new agreements were made.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 16, 2025.
What is Vera Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 2000 Sierra Point Parkway, Suite 1200, Brisbane, California 94005.
Filing Stats: 402 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2025-12-17 19:50:30
Key Financial Figures
- $0.001 — which registered Class A common stock, $0.001 par value per share VERA The Nasdaq
Filing Documents
- d26538d8k.htm (8-K) — 21KB
- 0001193125-25-323298.txt ( ) — 131KB
- vera-20251216.xsd (EX-101.SCH) — 3KB
- vera-20251216_lab.xml (EX-101.LAB) — 18KB
- vera-20251216_pre.xml (EX-101.PRE) — 11KB
- d26538d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vera Therapeutics, Inc. Date: December 17, 2025 By: /s/ Marshall Fordyce, M.D. Marshall Fordyce, M.D. Chief Executive Officer